Bessemer Group Inc. lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 333.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,484 shares of the company’s stock after buying an additional 1,142 shares during the quarter. Bessemer Group Inc.’s holdings in Neurocrine Biosciences were worth $150,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in NBIX. Acadian Asset Management LLC bought a new position in shares of Neurocrine Biosciences in the first quarter valued at $27,000. Covestor Ltd lifted its holdings in shares of Neurocrine Biosciences by 431.0% during the first quarter. Covestor Ltd now owns 377 shares of the company’s stock worth $35,000 after buying an additional 306 shares in the last quarter. Spire Wealth Management lifted its holdings in shares of Neurocrine Biosciences by 203.2% during the first quarter. Spire Wealth Management now owns 379 shares of the company’s stock worth $38,000 after buying an additional 254 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Neurocrine Biosciences by 53.0% during the first quarter. Signaturefd LLC now owns 436 shares of the company’s stock worth $44,000 after buying an additional 151 shares in the last quarter. Finally, CENTRAL TRUST Co bought a new position in shares of Neurocrine Biosciences in the third quarter worth $45,000. 91.56% of the stock is owned by institutional investors.
Neurocrine Biosciences Trading Down 0.6 %
Shares of NASDAQ:NBIX opened at $107.07 on Friday. The stock’s fifty day simple moving average is $99.88 and its two-hundred day simple moving average is $99.16. Neurocrine Biosciences, Inc. has a 1-year low of $89.04 and a 1-year high of $129.29. The stock has a market cap of $10.46 billion, a PE ratio of 61.89, a price-to-earnings-growth ratio of 1.08 and a beta of 0.50.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the company. SVB Leerink upgraded Neurocrine Biosciences from a “market perform” rating to an “outperform” rating in a research report on Monday, July 24th. Guggenheim upgraded Neurocrine Biosciences from a “neutral” rating to a “buy” rating and set a $145.00 target price for the company in a research report on Thursday, May 4th. Barclays cut their price target on shares of Neurocrine Biosciences from $131.00 to $125.00 in a report on Thursday, May 4th. HC Wainwright upped their price objective on shares of Neurocrine Biosciences from $140.00 to $146.00 and gave the company a “buy” rating in a research note on Monday. Finally, Mizuho upped their target price on Neurocrine Biosciences from $112.00 to $113.00 and gave the company a “neutral” rating in a research report on Monday. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $126.96.
Check Out Our Latest Analysis on Neurocrine Biosciences
Insider Activity
In related news, insider Jude Onyia sold 3,198 shares of Neurocrine Biosciences stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $107.37, for a total value of $343,369.26. Following the completion of the sale, the insider now owns 9,638 shares of the company’s stock, valued at approximately $1,034,832.06. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, insider Jude Onyia sold 3,198 shares of Neurocrine Biosciences stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $107.37, for a total value of $343,369.26. Following the completion of the sale, the insider now owns 9,638 shares of the company’s stock, valued at approximately $1,034,832.06. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kevin Charles Gorman sold 9,328 shares of Neurocrine Biosciences stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $107.40, for a total value of $1,001,827.20. Following the completion of the sale, the chief executive officer now directly owns 499,754 shares of the company’s stock, valued at approximately $53,673,579.60. The disclosure for this sale can be found here. Insiders sold a total of 14,658 shares of company stock valued at $1,574,152 in the last ninety days. 4.40% of the stock is currently owned by insiders.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.
Featured Stories
- Five stocks we like better than Neurocrine Biosciences
- NYSE Stocks Give Investors a Variety of Quality Options
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- What Are Dividends? Buy the Best Dividend Stocks
- How to Profit from These 3 Membership Club Stocks’ Strengths
- Investing in Travel Stocks Benefits
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
